Monday, July 1, 2013

Drug Discovery@nature.com 1 July 2013

Drug Discovery

Advertisement
iCell® & MyCell® Human Cells Reinvent Discovery Research
  • Ready-made iPSC-derived cells: Cardiomyocytes, neurons, hepatocytes, endothelial cells, and more
  • Made-to-order cells from your donor samples or CDI disease cell lines including cardiomyopathies / arrhythmias, neurological disorders, muscular dystrophies, and more
  • Enabling disease modeling, cell therapy, tissue engineering, and more
TABLE OF CONTENTS

1 July 2013

News
Analysis
Research Highlights
Research & Reviews
Careers


Nature Reviews Drug Discovery is on Twitter

Advertisement
FREE Nature Collection: Chronic Pain

This Nature Collection brings together articles that highlight recent advances towards understanding the risk factors and mechanisms that underlie chronic pain, and developing effective, non-addictive treatments for this highly prevalent condition.

FREE online until October 2013.

Produced with support from The NIH Pain Consortium 
 
 

News

Top

Silver makes antibiotics thousands of times more effective
doi:10.1038/nature.2013.13232
Ancient antimicrobial treatment could help to solve modern bacterial resistance.
Full Text

Blocking boozy memories reduces risk of relapse
doi:10.1038/nature.2013.13252
Molecule associated with learning and memory could be key to treating alcoholism.
Full Text

Simple molecule prevents mole rats from getting cancer
doi:10.1038/nature.2013.13236
Sugar matrix surrounding cells traps would-be tumours in long-lived mammal.
Full Text

Inducing translation
doi:10.1038/nbt.2602
The field of induced pluripotent stem cells is barely seven years old, but already three groups are close to launching clinical trials. Ken Garber looks into the prospects and perils.
Full Text

Analysis

Top

Interfacing with Ras
doi:10.1038/scibx.2013.588
A German team has identified a compound that disrupts a protein-protein interaction that localizes K-Ras to the cell membrane, thus selectively inhibiting tumor growth. The interface provides a new small molecule binding site for the handful of companies and academics working on ways to tackle the previously undruggable Ras family.
Full Text

RON's new role
doi:10.1038/scibx.2013.507
A team has shown that inhibiting the kinase RON could fight cancer metastasis by stimulating an antitumour immune response, building a case for focusing drug discovery efforts specifically against RON, which has long been neglected in favour of its relative, MET.
Full Text

Research Highlights

Top

Inflammatory disorders: Targeting TRAFs tames inflammation
doi:10.1038/nrd4029
Inhibition of tumour necrosis factor receptor-associated factors (TRAFs) through FBX03 could represent a novel potential anti-inflammatory therapeutic strategy.
Full Text

G protein-coupled receptors: Pioneering Frizzled family receptor structure solved
doi:10.1038/nrd4030
A crystal structure of the human Smoothened (SMO) receptor — an essential component of the Hedgehog signalling pathway — bound to an antitumour compound has been solved.
Full Text

Analgesia: A new player in neuropathic pain pathogenesis
doi:10.1038/nrd4031
The WNT family of proteins, which are involved in the regulation of cellular processes during nervous system development, have a key role in the pathogenesis of neuropathic pain.
Full Text

Research & Reviews

Top

Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases
doi:10.1038/nrd4010
Although nucleoside analogues have been used clinically for decades, efforts continue to improve response rates and reduce side effects. This article highlights recent progress in the development of new nucleoside and nucleotide analogues for cancer and viral diseases.
Full Text

The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer
doi:10.1038/nrc3521
This article discusses deep sequencing studies indicating that nearly 20% of human tumours harbour mutations in G-protein-coupled receptors (GPCRs) and the implications for GPCRs as therapeutic targets in oncology.
Full Text

The good, the bad and the ugly — TFH cells in human health and disease
doi:10.1038/nri3447
An increasing number of studies have highlighted new aspects of the differentiation and function of T follicular helper (TFH) cells in disease, which might represent targets for novel therapeutics.
Full Text

Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling
doi:10.1038/nature12205
Interfering with binding of PDEδ to KRAS with small molecules provides a novel opportunity to suppress oncogenic RAS signalling by altering its localization to endomembranes.
Full Text

Drug Discovery
JOBS of the week
Research Laboratory Head (M / F) Cancer Drug Discovery
Boehringer Ingelheim RCV GmbH & Co KG
Postdoctoral Training Fellow (Synthetic Chemist / PET Radiochemist)
Institute of Cancer Reseach
Senior Research Officer / Fellow
The University of Queensland, Institute for Molecular Bioscience
Postdoctoral Research Assistant
University of Dundee, College of Life Sciences
Postdoctoral Fellow ? Drug Discovery / GU Oncology
Moffitt Cancer Center & Research Institute
More Science jobs from
Drug Discovery
EVENT
Venomics: Drug Discovery from Nature?s Deadliest
04.11.13
New York, USA
More science events from

Careers

Top

Career snapshots archive
Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field.
Full Text

Top
Advertisement
SciBX is pleased to present:
SciBX Summit on Innovation in Drug Discovery and Development 2013
October 29-30, 2013
The Colonnade Hotel, Boston, MA, USA 
Click here for more information or to register for this conference today! 
 
nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.
Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount
(You will need to log in to be recognised as a nature.com registrant)

For further technical assistance, please contact our registration department

For print subscription enquiries, please contact our subscription department

For other enquiries, please contact our customer feedback department

Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA

Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS.

© Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.

nature publishing group

No comments: